Free Trial
NASDAQ:ETNB

89BIO Q2 2025 Earnings Report

89BIO logo
$9.33 -0.09 (-0.96%)
As of 10:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

89BIO EPS Results

Actual EPS
-$0.71
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.22
One Year Ago EPS
-$0.48

89BIO Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

89BIO Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

89BIO's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

89BIO Earnings Headlines

89bio to Participate in Upcoming Investor Conferences
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
89BIO (NASDAQ:ETNB) Receives $26.29 Consensus PT from Analysts
89bio: Promising As Pegozafermin Nears Phase 3 Readout
See More 89BIO Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 89BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89BIO and other key companies, straight to your email.

About 89BIO

89BIO (NASDAQ:ETNB), Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View 89BIO Profile

More Earnings Resources from MarketBeat